Upstream Bio reports Q1 net loss $40.6M; Phase 3 plans on track for 2027

Upstream Bio, Inc.

2026-Q1 EPS reported -$0.75 revenue$1,034,000

Cash, cash equivalents and short-term investments $294.6M as of March 31, 2026; expected to fund operations through 2027.
Net loss $40.6M vs $27.3M YoY; R&D expenses $36.6M (up from $25.8M) driven by clinical and manufacturing costs.
End-of-Phase 2 meetings with FDA planned mid-2026; Phase 3 initiations in severe asthma and CRSwNP expected Q1 2027.
Phase 2 VENTURE COPD trial capping enrollment at >400 participants; data now expected H2 2027.
Phase 2 VALOUR LTE study in severe asthma completed enrollment with >90% retention of eligible patients.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Upstream Bio, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $40.6 million for the quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Net income: Net loss was $40.6 million for the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Net loss was $40.6 million for the quarter ended March 31, 2026, compared to a net loss of $27.3 million for the same period in 2025.

View on SEC.gov

Browse all earnings releases →

Upstream Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-220578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.